Physician profile
Brett Lear Thorpe
NPI 1962432583
$12,111.28
in general payments reported to CMS, 2019-2025
45 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,576 · 2020: $855 · 2021: $1,526 · 2022: $1,832 · 2023: $2,275 · 2024: $2,387 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,292 · Education: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,292.28 |
| Education | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,794.08 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,060.88 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $799.42 | 2019-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $529.02 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $423.12 | 2019-2025 | Trulance, Relistor, Xifaxan |
| Gilead Sciences, INC. | $355.47 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $306.58 | 2021-2023 | |
| Qol Medical, LLC | $305.78 | 2019-2023 | Sucraid |
| Ardelyx, INC. | $272.21 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $232.61 | 2019-2024 | Ocaliva |
| Merck Sharp & Dohme LLC | $222.68 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $216.72 | 2024-2025 | Voquezna |
| Genzyme Corporation | $196.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $193.00 | 2022-2025 | Dupixent |
| Celgene Corporation | $181.08 | 2021-2023 | Zeposia |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Thorpe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.